PRELUDD-PAYMENT-SERVICES
23.5.2023 20:01:33 CEST | Business Wire | Press release
Preludd Payment Services, a leading player in the instore payment industry, has strengthened its service offering and entered the Global market by acquiring Amadis.
Preludd Payment Services, has completed the acquisition of Amadis, a leading provider of EMV card-present payment acceptance solutions. With this acquisition, the company now offers solutions at all stages of the payment chain for payment solution providers, banks, acquirers, payment terminal distributors and SoftPOS.
The combination of Preludd and Amadis will create a future market leader in payment solutions.
Connecting payment terminals
Founded in 2016, Preludd offers a white-label cloud-based payment platform that securely connects POS terminals in France. As a payment platform, the company forwards payment data from POS terminals to banks and private acquirers. It also facilitates POS terminal fleets and associated SIM cards management and logistics.
A strategic acquisition
The acquisition of Amadis will enable the two entities to leverage their skills to serve a common ambition: the emergence of a leading player in Global payment solutions, with priority given to SoftPOS. Amadis is a payment card software development company providing EMV payment acceptance solutions on off the shelf systems (COTS) like smartphones and tablets and also PCI POS terminal hardware.
The company provides out-of-the-box compliance software that implements the global standards and requirements of all global payment networks. It has a world-class client portfolio and its solutions are deployed globally.
By leveraging Amadis' 18 years of experience, Preludd will be able to offer new and innovative solutions to make payments more accessible to everyone around the world.
With Amadis based in North America, Preludd in France and Middle-East, the group has a presence that allows it to be as close as possible to global issues.
Key figures
Preludd / Amadis
- Over 78 million connections are routed to banks each month
- +290,000 terminals connected
- + 7.5 billion euros in transit each month
- + 60 employees who are experts in electronic payments
- 100% coverage of the global EMV payment networks
- Technology present in +55 million banking terminals & SoftPOS
- Goal to reach more than 10 million euros in turnover by 2025
About Preludd Payment Services
Preludd is a cloud-based white label payment gateway. Our PCI-DSS hosted infrastructure securely connects retail outlets to international payment networks and routes millions of transactions per month to banks. More information on https://preludd.com/
About Amadis
Amadis provides card processing software and secure payment acceptance solutions, including SoftPOS, to payment terminal manufacturers and service providers. Amadis develops its software according to standards (such as EMVco, PCI and Nexo) for universal and agnostic compliance. More information on https://www.amadis.ca/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom